Ovarian cancer often goes undetected until it spreads to other areas. In its late stages, it's harder to treat. Now there's an unconventional treatment being used to get rid of it. When her stomach ...

A retrospective study compared progression-free and overall survival of hyperthermic intraperitoneal chemotherapy with conventional intraperitoneal chemotherapy in patients with ovarian cancer.

Median progression-free survival (PFS) improved from 23 months with surgery alone to 25 months with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC), a nonsignificant difference. Post ...

In over 400 women at first epithelial ovarian cancer recurrence, those who received HIPEC had a median OS of 54.3 months compared with 45.8 months for those who did not (HR 0.73, 95% CI 0.56-0.96, P=0 ...

Amber and her family in the Volkswagen convertible she bought after learning she was cancer-free Amber used to live her life with anxiety and fear—always trying to stay within her comfort zone. She ...

Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer. Among patients with platinum-sensitive peritoneal ...

SCS combined with HIPEC may improve overall survival in PSROC patients compared to SCS alone, with a statistically significant benefit observed. The risk of severe complications, including anemia and ...

Patients with advanced ovarian cancer undergoing interval cytoreductive surgery who received paclitaxel-based hyperthermic intraperitoneal chemotherapy (HIPEC) during surgery appeared to have ...

They were given little hope of survival after being diagnosed with cancer, but now thanks to a little-known procedure they are continuing on with their lives. Kelly McCarley of Owings and Joe Finn of ...

Cytoreductive surgery removes tumors that have spread throughout your abdominal cavity. It’s often combined with another procedure called hyperthermic intraperitoneal chemotherapy. You may need ...